Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
about
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunitiesIn vivo spectral and fluorescence microscopy comparison of microvascular function after treatment with OXi4503, Sunitinib and their combination in Caki-2 tumors.Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian CarcinomaMagnetic resonance imaging identifies early effects of sunitinib treatment in human melanoma xenografts.A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs.Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models.Traumatic brain injury results in acute rarefication of the vascular network.The Effect of Sunitinib Treatment in Human Melanoma Xenografts: Associations with Angiogenic ProfilesProperdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reductionA host deficiency of discoidin domain receptor 2 (DDR2) inhibits both tumour angiogenesis and metastasis.Detecting functional changes with [(18)F]FAZA in a renal cell carcinoma mouse model following sunitinib therapy.Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis.
P2860
Q27025579-0452B0F4-1C98-46D9-934F-654712D21873Q33738607-DAC70A26-5F7A-4DCB-BF26-1EA23E4B4B47Q33746474-F8E7148D-76EE-49A4-81C3-F26E18CFCB9BQ34249349-16FB8A51-B820-4A36-BDDA-1F8D5F963B06Q34687036-0D198844-8B55-4B3F-BBED-13CA5F8E135DQ35742534-4CFA3055-43CD-4DB9-908C-F431C54FB1C4Q35843084-11A7414A-C5C7-4234-8C16-A4DC4DC40394Q35993104-18297712-6463-4507-B4BB-6311C8D5B995Q36319052-9EE32EA0-8817-4667-B669-9391E9059685Q37627013-9A96B334-FFFE-4360-B78C-7718CB556373Q37718288-824465C2-952F-4767-BD59-566CD29169B9Q38892371-379C1FEA-D2A1-4A82-839B-F76C44816119Q39051468-5AD7F0BB-576F-4A49-BBBE-FD8C67A13DFEQ41505826-320F4151-F3F9-4F59-9921-58C21075FC7FQ41610199-1103AEC5-F263-4225-9EC0-117E69FE3BF7
P2860
Sunitinib treatment does not improve blood supply but induces hypoxia in human melanoma xenografts.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Sunitinib treatment does not i ...... in human melanoma xenografts.
@ast
Sunitinib treatment does not i ...... in human melanoma xenografts.
@en
Sunitinib treatment does not i ...... in human melanoma xenografts.
@nl
type
label
Sunitinib treatment does not i ...... in human melanoma xenografts.
@ast
Sunitinib treatment does not i ...... in human melanoma xenografts.
@en
Sunitinib treatment does not i ...... in human melanoma xenografts.
@nl
prefLabel
Sunitinib treatment does not i ...... in human melanoma xenografts.
@ast
Sunitinib treatment does not i ...... in human melanoma xenografts.
@en
Sunitinib treatment does not i ...... in human melanoma xenografts.
@nl
P2860
P356
P1433
P1476
Sunitinib treatment does not i ...... in human melanoma xenografts.
@en
P2093
Marit N Leinaas
Trude G Simonsen
P2860
P2888
P356
10.1186/1471-2407-12-388
P407
P577
2012-09-04T00:00:00Z
P5875
P6179
1018056010